BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Schering-Plough  Europe  submitted  on  2  July  2004  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Noxafil, 
through  the  centralised  procedure.  After  agreement  by  the  CHMP  on  20 March  2004  this  medicinal 
product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 
1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr Ian Hudson 
Co-Rapporteur:  Dr Eric Abadie 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 25 April 2001. The Scientific Advice 
pertained to clinical aspects of the dossier.  
Licensing status: 
A new application was filed in the following countries: USA. 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 2 July 2004. 
The procedure started on 19 July 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  1  October 
2004.  The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 5 
October 2004. 
During  the  meeting  on  15  –  18 November 2004, the CHMP agreed on the consolidated List of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions was  sent  to  the 
applicant on 18 November 2004. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 15 March 
2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 28 April 2005. 
During  the  CHMP  meeting  on  23  –  26  May  2005,  the  CHMP agreed on a List of outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The applicant submitted the responses to the CHMP List of outstanding issues on 15 June 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding Issues to all CHMP members on 5 July 2005. 
During the meeting  on 25 – 27 July 2005, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Noxafil  on  27  July  2005.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 26 July 2005. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 25 October 2005. 
1/1 

EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
